# Cancer Immunotherapeutic (PCI) Strategy in Triple Negative Breast Cancer Patients

> **NCT07300475** · PHASE1 · NOT_YET_RECRUITING · sponsor: **Washington University School of Medicine** · enrollment: 30 (estimated)

## Conditions studied

- Triple Negative Breast Cancer

## Interventions

- **DRUG:** Paclitaxel
- **DRUG:** Carboplatin
- **DRUG:** Pembrolizumab
- **DRUG:** Doxorubicin
- **DRUG:** Cyclophosphamide
- **BIOLOGICAL:** Personalized cancer immunotherapeutic (PCI)
- **DRUG:** AB248 (CD8-selective IL-2 mutein fusion protein)
- **OTHER:** pVAC tools neoantigen prediction algorithm
- **DRUG:** poly-ICLC

## Key facts

- **NCT ID:** NCT07300475
- **Lead sponsor:** Washington University School of Medicine
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-06-30
- **Primary completion:** 2030-04-08
- **Final completion:** 2035-03-09
- **Target enrollment:** 30 (ESTIMATED)
- **Last updated:** 2026-05-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07300475

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07300475, "Cancer Immunotherapeutic (PCI) Strategy in Triple Negative Breast Cancer Patients". Retrieved via AI Analytics 2026-07-17 from https://api.ai-analytics.org/clinical/NCT07300475. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*